Werewolf Therapeutics, Inc. (HOWL)Healthcare | Biotechnology | Watertown, United States | NasdaqCM
0.94 USD
-0.03
(-2.833%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.93 -0.02 (-0.018%) ⇩ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:35 a.m. EDT
The investment case for Werewolf Therapeutics is currently broken by a catastrophic multi-year decline and a deteriorating balance sheet. The stock has erased nearly 93% of its value over the last four years, with every single year showing negative returns, signaling a persistent failure to execute or deliver value. Fundamentally, the company is burning cash aggressively with negative gross margins and no path to profitability visible in the near term. The recent price action shows a brief, sharp spike to $0.87 followed by a collapse back to $0.40, suggesting the previous rally was a dead cat bounce rather than a reversal. With no dividend to provide income and a massive gap between the current price and the analyst target of $7.00 (which likely assumes a binary event like a successful trial readout), the risk/reward profile is skewed heavily toward capital preservation. Investors should avoid this name until there is concrete evidence of revenue growth or a stabilized burn rate. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.584862 |
| AutoARIMA | 0.586775 |
| AutoETS | 0.591838 |
| MSTL | 0.603970 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 17% |
| H-stat | 59.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | 0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.439 |
| Market Cap | 45,843,496 |
| Forward P/E | -1.60 |
| Beta | 0.29 |
| Profit Margins | -164.82% |
| Website | https://werewolftx.com |
As of Aug. 22, 2026, 2:35 a.m. EDT: Speculators are overwhelmingly positioning for further downside via heavy put volume relative to call volume. While there is significant call volume at the $2.50 strike (likely a hedge against dilution or a speculative 'lottery ticket' bet on a clinical milestone), the lack of any In-The-Money call buying and the dominance of ITM puts indicate a consensus view that the stock will struggle to recover from current levels. Implied volatility remains elevated, reflecting uncertainty rather than bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2530769 |
| Address1 | 200 Talcott Ave |
| Address2 | 2nd Floor |
| All Time High | 23.99 |
| All Time Low | 0.27 |
| Ask | 1.22 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 39,587,630 |
| Average Daily Volume3 Month | 7,015,287 |
| Average Volume | 7,015,287 |
| Average Volume10Days | 39,587,630 |
| Beta | 0.287 |
| Bid | 0.707 |
| Bid Size | 2 |
| Book Value | 0.335 |
| City | Watertown |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9433 |
| Current Ratio | 2.911 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.03 |
| Day Low | 0.93 |
| Display Name | Werewolf Therapeutics |
| Earnings Timestamp | 1,785,501,000 |
| Earnings Timestamp End | 1,793,363,400 |
| Earnings Timestamp Start | 1,793,363,400 |
| Ebitda | -21,921,000 |
| Ebitda Margins | -1.04386 |
| Enterprise To Ebitda | -1.088 |
| Enterprise To Revenue | 1.136 |
| Enterprise Value | 23,856,498 |
| Eps Current Year | -0.89 |
| Eps Forward | -0.59 |
| Eps Trailing Twelve Months | -0.71 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.43344 |
| Fifty Day Average Change | 0.50986004 |
| Fifty Day Average Change Percent | 1.1763105 |
| Fifty Two Week Change Percent | -25.307692 |
| Fifty Two Week High | 2.38 |
| Fifty Two Week High Change | -1.4367001 |
| Fifty Two Week High Change Percent | -0.60365546 |
| Fifty Two Week Low | 0.27 |
| Fifty Two Week Low Change | 0.6733 |
| Fifty Two Week Low Change Percent | 2.4937036 |
| Fifty Two Week Range | 0.27 - 2.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,789,400,000 |
| Float Shares | 47,916,735 |
| Forward Eps | -0.59 |
| Forward P E | -1.5988137 |
| Free Cashflow | -12,233,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Fullday Change | -0.0275 |
| Fullday Change Percent | -2.83271 |
| Fullday Price | 0.9251 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.2469 |
| Gross Profits | -5,185,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.014040001 |
| Held Percent Institutions | 0.29092 |
| Implied Shares Outstanding | 48,599,066 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. |
| Long Name | Werewolf Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 45,843,496 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_560735713 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,613,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 47,126,514 |
| Number Of Analyst Opinions | 3 |
| Open | 0.9747 |
| Operating Cashflow | -30,148,000 |
| Operating Margins | 0.40652 |
| Payout Ratio | 0.0 |
| Phone | 617 952 0555 |
| Post Market Change | -0.01819998 |
| Post Market Change Percent | -1.9293947 |
| Post Market Price | 0.9251 |
| Post Market Time | 1,787,961,531 |
| Previous Close | 0.9708 |
| Price Eps Current Year | -1.0598876 |
| Price Hint | 4 |
| Price To Book | 2.815821 |
| Price To Sales Trailing12 Months | 2.1830237 |
| Profit Margins | -1.6482401 |
| Quick Ratio | 2.796 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0275 |
| Regular Market Change Percent | -2.83271 |
| Regular Market Day High | 1.03 |
| Regular Market Day Low | 0.93 |
| Regular Market Day Range | 0.93 - 1.03 |
| Regular Market Open | 0.9747 |
| Regular Market Previous Close | 0.9708 |
| Regular Market Price | 0.9433 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 2,280,861 |
| Return On Assets | -0.27387 |
| Return On Equity | -1.19859 |
| Revenue Per Share | 0.439 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 48,599,066 |
| Shares Percent Shares Out | 0.022 |
| Shares Short | 1,067,589 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 934,340 |
| Short Name | Werewolf Therapeutics, Inc. |
| Short Percent Of Float | 0.026600001 |
| Short Ratio | 1.72 |
| Source Interval | 15 |
| State | MA |
| Symbol | HOWL |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 21,987,000 |
| Total Cash Per Share | 0.452 |
| Total Debt | 0 |
| Total Revenue | 21,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.65294 |
| Two Hundred Day Average Change | 0.29036003 |
| Two Hundred Day Average Change Percent | 0.44469637 |
| Type Disp | Equity |
| Volume | 2,280,861 |
| Website | https://werewolftx.com |
| Zip | 2,472 |